Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, Wolters PL, Steinberg SM, Baker EH, Delbrook CP, Stetler-Stevenson M, Fry TJ, Stroncek DF, Mackall CL. Shah NN, et al. Among authors: shalabi h. J Clin Oncol. 2021 May 20;39(15):1650-1659. doi: 10.1200/JCO.20.02262. Epub 2021 Mar 25. J Clin Oncol. 2021. PMID: 33764809 Free PMC article. Clinical Trial.
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL. Fry TJ, et al. Among authors: shalabi h. Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20. Nat Med. 2018. PMID: 29155426 Free PMC article. Clinical Trial.
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
Shalabi H, Kraft IL, Wang HW, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES, Lee DW, Shern JF, Fry TJ, Shah NN. Shalabi H, et al. Haematologica. 2018 May;103(5):e215-e218. doi: 10.3324/haematol.2017.183459. Epub 2018 Feb 1. Haematologica. 2018. PMID: 29419431 Free PMC article. No abstract available.
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.
Shalabi H, Yuan CM, Kulshreshtha A, Dulau-Florea A, Salem D, Gupta GK, Roth M, Filie AC, Yates B, Delbrook C, Derdak J, Mackall CL, Lee DW, Fry TJ, Wayne AS, Stetler-Stevenson M, Shah NN. Shalabi H, et al. Pediatr Blood Cancer. 2020 Apr;67(4):e28149. doi: 10.1002/pbc.28149. Epub 2020 Jan 25. Pediatr Blood Cancer. 2020. PMID: 31981407 Free PMC article.
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ. Shah NN, et al. Among authors: shalabi h. J Clin Oncol. 2020 Jun 10;38(17):1938-1950. doi: 10.1200/JCO.19.03279. Epub 2020 Apr 14. J Clin Oncol. 2020. PMID: 32286905 Free PMC article. Clinical Trial.
51 results